What Is Survodutide?
Survodutide is an investigational peptide medicine designed to activate the glucagon receptor and the glucagon-like peptide-1 receptor, shortened to GLP-1 receptor. Investigational means it is being studied but has not received routine marketing approval. It is not an approved medicine in the United Kingdom, European Union or United States as of 9 November 2026.
The molecule began as BI 456906. It was created from a modified glucagon sequence and fitted with a fatty-acid-related side chain that helps it remain in the circulation for longer. The design supports weekly administration in clinical trials. A molecule that activates a receptor is called an agonist, so survodutide is described as a glucagon and GLP-1 receptor dual agonist.
Boehringer Ingelheim, a German pharmaceutical company that develops and manufactures human medicines, leads clinical development. The programme originated through Zealand Pharma, a Danish biotechnology company specialising in peptide medicines. Boehringer Ingelheim licensed rights to develop and commercialise the compound.
Survodutide has substantial human evidence. Randomised Phase 2 studies examined type 2 diabetes, obesity and metabolic dysfunction-associated steatohepatitis. MASH is a form of fatty liver disease in which excess liver fat is accompanied by inflammation and cell injury, sometimes with fibrosis, meaning scar tissue. Phase 3 studies have since reported weight and liver-fat findings. This is a far stronger evidence base than laboratory-only research, but the medicine still awaits regulatory assessment.
What is survodutide made from?
Survodutide is an engineered peptide based on glucagon. Glucagon is a natural 29-amino-acid hormone made by alpha cells in the pancreas. Amino acids are the building blocks joined together to form peptides and proteins. Natural glucagon mainly protects against low blood glucose by telling the liver to release glucose.
Researchers changed selected positions in the glucagon sequence so that the new peptide could also activate the GLP-1 receptor with a planned balance between the two targets. Published discovery work describes an unnatural amino acid and a glycine-serine linker at position 24. An unnatural amino acid is a chemically produced building block not normally incorporated into human proteins by the genetic code. A linker is a chemical bridge joining two parts of a molecule.
The linker carries a C18 di-acid fatty group. C18 means that the fatty chain contains 18 carbon atoms. This fatty component encourages reversible association with albumin, a common blood protein. Albumin binding helps slow enzyme breakdown and kidney clearance. Clearance is the process by which the body removes a substance from the circulation.
Survodutide is not natural glucagon, even though glucagon provided its structural starting point. It is also not oxyntomodulin, semaglutide, tirzepatide, retatrutide or mazdutide. Mazdutide reaches the same two broad receptor types but was designed as an oxyntomodulin analogue and has a separate chemical identity and evidence programme.
How do the two receptor systems work?
GLP-1 is a gut hormone released after food. It is an incretin, meaning that it strengthens insulin release when blood glucose is raised. Insulin helps cells use glucose and reduces excessive glucose output from the liver. GLP-1 also slows gastric emptying, the movement of food from the stomach into the small intestine, and acts on appetite pathways in the brain.
Glucagon often works in the opposite direction for blood glucose. It signals the liver to break down stored glycogen and produce glucose. Glycogen is a branched form in which the body stores glucose. This prevents blood glucose from falling too low between meals or during prolonged activity.
Glucagon also changes fat and amino-acid metabolism and can increase energy expenditure. Amino-acid metabolism refers to how the body uses and disposes of the building blocks of protein. The liver expresses many glucagon receptors, which is one reason dual agonists are being studied in fatty liver disease.
A successful dual agonist must achieve a clinically useful net effect. GLP-1 activity may restrain food intake and support glucose control, while glucagon activity may add energy and liver effects. If glucagon activity were excessive, it could oppose glucose lowering. The correct balance cannot be inferred from the names of the receptors. It must be established with pharmacology and human trials.
How is survodutide thought to affect weight?
The GLP-1 component is expected to reduce hunger and food intake. Slower gastric emptying may contribute, especially early in treatment, although this effect can become less pronounced with continued exposure. Brain regions involved in appetite and reward also receive GLP-1-related signals.
The glucagon component is intended to influence energy expenditure and nutrient handling. In preclinical experiments, BI 456906 reduced food intake and increased energy expenditure. Preclinical means work carried out before or outside the main human clinical programme, usually in cells or animals. These experiments help identify mechanisms but cannot determine the size of the effect in people.
Human weight change combines several processes. Reduced food intake, altered food preference, nausea, changes in energy expenditure, loss of fat and loss of lean tissue can all contribute. Lean tissue includes muscle, organs, water and other non-fat components. A body-composition scan can estimate these compartments, but it cannot show that every kilogram lost came from one pathway.
SYNCHRONIZE-1 included imaging substudies. The investigators reported reductions in visceral fat and liver fat. Visceral fat is fat stored deep in the abdomen around organs. These findings are biologically interesting, but they came from smaller subsets of the full trial and should not replace the main whole-trial outcomes.
Why is survodutide being studied in liver disease?
Metabolic dysfunction-associated steatotic liver disease, shortened to MASLD, begins with excess fat in the liver in a person with metabolic risk factors. The older term was non-alcoholic fatty liver disease. When fat accumulation is accompanied by liver-cell injury and inflammation, the condition is called metabolic dysfunction-associated steatohepatitis, or MASH. Its older name was non-alcoholic steatohepatitis.
Fibrosis is the laying down of scar tissue. Fibrosis stages F1 to F3 describe increasing scarring short of cirrhosis. Cirrhosis, or F4, is advanced remodelling of the liver and has different risks and treatment questions.
Weight loss can reduce liver fat and improve MASH. Survodutide may also have liver effects connected with glucagon-receptor signalling. It is difficult to separate these possibilities in a standard trial because weight, appetite, insulin sensitivity, inflammation and liver metabolism change together.
Magnetic resonance imaging-proton density fat fraction, shortened to MRI-PDFF, estimates the proportion of liver tissue signal attributable to fat. It is non-invasive and useful for repeated measurements. A relative reduction of at least 30 per cent has been associated with a greater chance of histological improvement, but MRI-PDFF does not replace a biopsy for every question.
Histology means examining tissue under a microscope. A liver biopsy can assess fat, inflammation, cell injury and fibrosis, but it samples only a small part of the liver and carries procedural burdens. That is why liver trials may combine biopsy, imaging and blood-based or stiffness-based non-invasive tests.
When was survodutide first documented?
The programme grew from longer-running work on glucagon and GLP-1 co-agonists. Zealand Pharma developed peptide technology in this area and entered a collaboration with Boehringer Ingelheim in 2011. BI 456906 then moved through laboratory testing and early human studies before receiving the name survodutide.
| Year | Development |
|---|---|
| 2011 | Boehringer Ingelheim and Zealand Pharma began the licensed development relationship behind the programme |
| 2017 to 2019 | BI 456906 entered early clinical testing |
| 2022 | The detailed discovery and preclinical pharmacology paper was published |
| 2023 to 2024 | Phase 2 findings were published in type 2 diabetes, obesity and MASH |
| 2023 | The global SYNCHRONIZE Phase 3 obesity programme began |
| 2024 | The US FDA granted Breakthrough Therapy designation for the MASH programme |
| 2026 | SYNCHRONIZE-1 and SYNCHRONIZE-MASLD Phase 3 results were published |
| September 2026 | Survodutide remains investigational while further obesity and liver programmes continue |
Breakthrough Therapy designation is a United States development pathway for an investigational medicine that has preliminary evidence of substantial improvement over available therapy for a serious condition. It can increase regulatory interaction and speed aspects of development. It is not FDA approval and does not establish final safety or benefit.
How is survodutide synthesised and manufactured?
Survodutide is manufactured as a defined chemical substance rather than extracted from pancreas or gut tissue. The peptide chain can be assembled from protected amino-acid building blocks. Therapeutic peptide production may use solid-phase peptide synthesis, fragment joining or a combined process depending on scale and the manufacturer's validated method.
In solid-phase synthesis, one protected amino acid is attached to a resin, an insoluble polymer bead. Additional amino acids are added one at a time. Temporary protective groups prevent reactions at the wrong chemical sites. Each cycle activates the next building block, forms a peptide bond and washes away unused reagents and by-products.
Survodutide manufacture also has to install its non-standard amino acid, glycine-serine linker and C18 fatty di-acid at the intended positions. The site and chemistry of this attachment influence receptor activity, albumin association, solubility and stability. A peptide with the right amino-acid count but the wrong side-chain attachment would not be the same substance.
After assembly, the peptide is removed from the resin and remaining protective groups are taken off. The crude mixture can contain chains missing an amino acid, altered side chains, incomplete fatty-group attachment and residual solvents. Preparative high-performance liquid chromatography, or HPLC, separates many impurities. Mass spectrometry checks molecular mass, while peptide mapping and other analytical methods help confirm sequence and attachment sites.
Sterile medicine manufacture then requires validated control of identity, concentration, sterility, bacterial endotoxins, particles, container closure and stability. Endotoxins are inflammatory parts of bacterial cell walls. They can remain even when no living bacteria are detected.
A research-market vial with the name survodutide cannot be presumed to match the clinical substance. HPLC area purity does not establish the full sequence, side-chain position, quantity, sterility, endotoxin level or storage stability. Survodutide has no approved commercial medicine whose label can be borrowed by an unrelated product.
What did the early type 2 diabetes trial find?
A Phase 2 trial enrolled 413 adults aged 18 to 75 with type 2 diabetes. Participants had HbA1c between 7.0 and 10.0 per cent and BMI between 25 and 50 kg/m² while taking metformin. Metformin is a widely used tablet that reduces glucose production by the liver and improves the body's response to insulin.
HbA1c estimates average blood glucose over roughly two to three months by measuring glucose attached to haemoglobin in red blood cells. BMI relates weight to height and is used to define trial groups. It does not directly measure body fat or individual health.
Participants were randomly allocated to several once-weekly or twice-weekly survodutide regimens, placebo, or once-weekly semaglutide up to 1.0 mg. Random allocation uses chance to reduce systematic differences between groups. Placebo is a comparison treatment without the investigational active ingredient. The semaglutide arm was open-label, meaning participants and investigators knew it was being given, while the other assignments were blinded.
After 16 weeks, HbA1c fell across the survodutide groups. The largest adjusted mean fall reported was 1.71 percentage points in one once-weekly group, while the semaglutide comparison fell 1.47 points. Mean weight change ranged with administration level and reached minus 8.7 per cent in one twice-weekly group, compared with minus 5.3 per cent with semaglutide.
This was a short dose-finding study, not proof that survodutide is superior to semaglutide for routine diabetes care. The semaglutide comparison was open-label, several regimens were tested, and 16 weeks is much shorter than long-term diabetes treatment. The administration levels document the experiment rather than recommend a schedule.
What did the Phase 2 obesity trial find?
The Phase 2 obesity trial enrolled 387 adults with BMI of at least 27 kg/m². Participants did not have diabetes. They were assigned to target weekly levels of 0.6 mg, 2.4 mg, 3.6 mg or 4.8 mg, or placebo. The trial was randomised, double-blind and placebo-controlled. Double-blind means participants and the main study team did not know the assigned treatment during the blinded period.
Administration levels increased over time to improve tolerability. This process is called dose escalation or titration. The treatment period lasted 46 weeks. The study tested several escalation schedules because nausea and other gastrointestinal effects had limited tolerability in earlier work.
Under the main planned analysis, mean weight change at week 46 was minus 6.2 per cent with 0.6 mg, minus 12.5 per cent with 2.4 mg, minus 13.2 per cent with 3.6 mg and minus 14.9 per cent with 4.8 mg, compared with minus 2.8 per cent with placebo. A separate analysis among participants who reached and remained on the highest target generated the widely quoted figure of about 18.7 per cent.
The second figure should not be presented as the result for everyone assigned to survodutide. It describes a selected analysis and is affected by whether participants tolerated escalation and stayed in the trial. This is an example of why an apparently simple percentage needs its study population and analysis attached.
Adverse events occurred in 91 per cent of survodutide recipients and 75 per cent of placebo recipients. They were mainly gastrointestinal. Treatment discontinuation was more common with survodutide, especially with faster escalation. Slower escalation reduced some intolerance, which influenced the later Phase 3 design.
What did the Phase 2 MASH trial find?
The 48-week Phase 2 trial enrolled adults with biopsy-confirmed MASH and fibrosis stages F1 to F3. Participants were assigned to weekly survodutide target levels of 2.4 mg, 4.8 mg or 6.0 mg, or placebo. The first 24 weeks were used for rapid escalation and the next 24 for maintenance.
The primary outcome was improvement in MASH without worsening of fibrosis. This means liver fat, inflammation and cell injury improved by the study's microscopic scoring rules while the fibrosis stage did not become worse.
In the main analysis, this outcome occurred in 47 per cent of the 2.4 mg group, 62 per cent of the 4.8 mg group and 43 per cent of the 6.0 mg group, compared with 14 per cent of the placebo group. A different analysis restricted to participants with paired, readable biopsies produced higher percentages, including the frequently reported figure of 83 per cent in one survodutide group versus 18 per cent with placebo.
Fibrosis improvement by at least one stage without worsening of MASH occurred more often in the survodutide groups than with placebo, but the study was not large enough to settle every comparison between levels. Biopsy availability and treatment discontinuation influenced the analysis population.
Gastrointestinal adverse effects were again common. The rapid escalation used in the trial may have contributed. The findings supported Phase 3 testing but did not amount to marketing approval for MASH.
What did SYNCHRONIZE-1 find?
SYNCHRONIZE-1 was a global Phase 3 trial in adults with obesity without type 2 diabetes. It enrolled 725 treated participants across 14 countries, including the United Kingdom and United States. Participants had BMI of at least 30 kg/m², or at least 27 kg/m² with an obesity-related health problem. They were assigned in equal proportions to target weekly levels of 3.6 mg or 6.0 mg survodutide, or placebo. All groups received lifestyle counselling.
At week 76, the treatment-regimen estimand found average weight changes of minus 12.2 per cent with 3.6 mg, minus 13.0 per cent with 6.0 mg and minus 5.4 per cent with placebo. A treatment-regimen estimand aims to reflect outcomes regardless of treatment discontinuation or other specified events. At least 5 per cent weight reduction occurred in 72.6 per cent, 71.9 per cent and 46.3 per cent respectively.
The efficacy estimand estimated what happened under continued assigned treatment without specified events. Under that analysis, the reported mean loss reached 16.6 per cent at 6.0 mg, compared with 3.2 per cent with placebo. The 16.6 per cent figure is scientifically valid for its question, but it should not replace the treatment-regimen result when explaining what happened across all assigned participants.
Gastrointestinal symptoms occurred in 80.9 per cent of the 3.6 mg group, 89.7 per cent of the 6.0 mg group and 47.9 per cent of the placebo group. They were usually mild or moderate. Nineteen per cent of survodutide-treated participants discontinued because of gastrointestinal events, compared with 2.9 per cent on placebo. That withdrawal rate is an important part of the benefit-risk picture.
Imaging substudies reported reductions in liver and visceral fat with limited proportional loss of lean mass. Substudies include only participants with the relevant scans and usable data, so their findings should be read as supportive rather than as outcomes measured in all 725 participants.
What did SYNCHRONIZE-2 find?
SYNCHRONIZE-2 extended Phase 3 evidence to adults with obesity and type 2 diabetes. Its published report appeared on 1 October 2026. The multinational trial randomly assigned 752 participants to two survodutide groups or placebo for 76 weeks. Double blinding concealed the assignment from participants and study teams.
Under the treatment-regimen analysis, average weight changes were −8.2% and −9.8% with survodutide versus −3.9% with placebo. At least 5% weight loss occurred in 57.6% and 64.5% versus 35.1%. HbA1c reductions were 0.9 and 0.8 percentage points versus 0.2.
Gastrointestinal adverse events occurred in 72.8% and 77.7% versus 38.6%. They were generally described as mild to moderate and transient, although frequent symptoms still matter to tolerability. This analysis included outcomes despite treatment interruption, discontinuation or additional weight-management therapy. It should not be mixed with hypothetical continued-treatment estimates.
This provides human Phase 3 evidence in diabetes, alongside the separate SYNCHRONIZE-1 population without diabetes. A separate cardiovascular outcomes trial, SYNCHRONIZE-CVOT, subsequently reported cardiovascular safety findings in November 2026. Neither trial establishes cardiovascular benefit or regulatory approval.
What did the SYNCHRONIZE-CVOT cardiovascular trial find?
SYNCHRONIZE-CVOT was a Phase 3 study designed to assess cardiovascular safety in 5,530 adults with overweight or obesity who had established cardiovascular disease, chronic kidney disease, or at least two weight-related complications or cardiovascular risk factors. Participants were randomly assigned to weekly survodutide or placebo. The trial was double-blind, meaning neither participants nor investigators knew which treatment an individual received during the study. Results were presented on 9 November 2026 and published in *The Lancet*.
The main outcome was a composite of five serious cardiovascular events: cardiovascular death, non-fatal heart attack, non-fatal stroke, a procedure to restore blood flow to the heart, or a heart-failure event. A composite endpoint counts the first occurrence of any event in the defined group. The reported hazard ratio for survodutide versus placebo was 0.89, with a 95% confidence interval of 0.67 to 1.18. A hazard ratio compares how quickly events occur between groups; 1 would mean no difference. The confidence interval describes the range of effects compatible with the data under the statistical model.
The trial met its prespecified non-inferiority criterion, meaning that the results ruled out an unacceptably large increase in cardiovascular risk according to the study's chosen statistical margin. This is evidence of cardiovascular safety within the trial's design, not proof that survodutide prevents heart attacks, strokes or cardiovascular deaths. The confidence interval includes both a possible reduction and a possible increase in events.
The investigators also reported reductions at week 72 of up to 13.7% in body weight with survodutide versus 2.0% with placebo, up to 6.68 mmHg versus 1.76 mmHg in systolic blood pressure, and up to 11.96 cm versus 2.74 cm in waist circumference. These figures come from a supplementary analysis estimating effects under continued treatment without specified intervening events. They must not be confused with the primary treatment-regimen analysis, which considers outcomes regardless of whether participants stopped treatment or used other therapies. Changes in blood pressure and waist size are relevant health markers, but they are not themselves proof of fewer cardiovascular events.
Gastrointestinal tolerability remained a substantial limitation. Treatment discontinuation attributed to gastrointestinal adverse events occurred in 19.3% and 20.8% of the two survodutide groups, compared with 1.9% on placebo. The developer noted that the original protocol allowed limited flexibility to slow escalation or adjust treatment when symptoms occurred. That may help explain discontinuation, but it does not remove the observed difference between groups.
The findings strengthen the human evidence for cardiovascular safety in the population studied. They do not establish safety for every population, exclude rare harms or replace regulatory assessment. Survodutide remained investigational on 9 November 2026; Boehringer Ingelheim said it was moving towards regulatory submissions.
What did SYNCHRONIZE-MASLD find?
SYNCHRONIZE-MASLD was a 48-week Phase 3 trial in adults with obesity and at-risk MASLD. At-risk meant liver fat plus evidence suggesting inflammation or fibrosis on non-invasive tests, or a recent biopsy confirming MASH. Of 218 randomised participants, 216 received at least one treatment.
Participants were assigned in a two-to-one ratio to survodutide with a 6.0 mg weekly target or placebo. Two-to-one means that about two people received survodutide for every one who received placebo. The first 24 weeks increased exposure gradually and the next 24 maintained the target where tolerated.
The two main outcomes were at least a 30 per cent relative reduction in liver fat measured by MRI-PDFF and percentage change in body weight. Under the efficacy estimand, 84.2 per cent of the survodutide group and 24.3 per cent of the placebo group achieved the liver-fat threshold. Average weight change was minus 12.2 per cent and minus 1.0 per cent respectively.
Under the treatment-regimen estimand, which included outcomes despite discontinuation and other specified events, the liver-fat response occurred in 68.5 per cent with survodutide and 28.6 per cent with placebo. Weight change was minus 8.7 per cent and minus 1.4 per cent respectively.
The trial shows a substantial effect on measured liver fat in this selected group. It was not designed to prove fewer cases of cirrhosis, liver failure, transplantation or death. It also did not use repeat biopsy as the co-primary outcome. Phase 3 LIVERAGE trials are examining histological and longer-term clinical questions in people with MASH and fibrosis or cirrhosis.
What happened in participants with cirrhosis?
An early pharmacokinetic study examined survodutide in people with compensated or decompensated cirrhosis. Compensated cirrhosis means severe liver scarring is present but the liver still performs its main functions without major failure-related complications. Decompensated cirrhosis means complications such as fluid accumulation, bleeding or impaired brain function have developed.
The study was designed mainly to understand exposure and tolerability, not to demonstrate treatment of cirrhosis. Small pharmacokinetic cohorts cannot establish that a medicine prevents liver failure. They can show whether liver impairment changes blood concentrations enough to affect later study design.
The dedicated LIVERAGE-Cirrhosis Phase 3 trial is intended to address a different question: whether longer treatment improves disease measures and clinical outcomes in people with MASH-related cirrhosis. Until those results are available, early exposure data should not be presented as evidence of benefit in advanced liver disease.
What are the main safety findings?
Nausea, vomiting, diarrhoea, constipation and other gastrointestinal symptoms are the clearest recurring adverse effects. They were most common during escalation. Slower escalation can improve tolerability for some participants, but it does not remove the class effect.
Treatment discontinuation deserves equal prominence with event frequency. In SYNCHRONIZE-1, about one in five survodutide-treated participants stopped because of gastrointestinal adverse events. If a person cannot remain on treatment, an efficacy estimate based on continued treatment will not describe their experience.
Heart rate increased in some trials. The clinical meaning of a modest average increase depends on individual health and longer follow-up. The November 2026 SYNCHRONIZE-CVOT study met its prespecified cardiovascular non-inferiority criterion, but did not prove cardiovascular benefit. Blood-pressure improvements do not remove uncertainty about uncommon or longer-term harms.
Glucagon signalling can raise glucose, while GLP-1 signalling can lower it. Human studies found an overall glucose-lowering effect in type 2 diabetes, showing that the tested receptor balance did not behave like glucagon alone. Low blood glucose can still become more likely when an incretin medicine is combined with insulin or a sulfonylurea, a class of tablets that increases insulin release.
Pancreatitis, gallbladder disease, severe gastrointestinal disease and effects in pregnancy are important areas for the broader GLP-1 medicine class. Pancreatitis is inflammation of the pancreas. Survodutide-specific warnings will ultimately depend on the complete regulatory review and approved product information if authorisation is granted.
MASH trials also require attention to liver safety. A fall in liver enzymes or liver fat is encouraging, but investigators still monitor for drug-induced liver injury, worsening liver function and complications in people with advanced disease.
Rare harms can remain uncertain even after Phase 3 because trials contain hundreds or thousands of people rather than millions. Post-marketing monitoring, if the medicine is approved, would be needed to identify uncommon events and real-world patterns.
How does survodutide compare with mazdutide?
Both activate GLP-1 and glucagon receptors, but they are not interchangeable. Survodutide is based on a modified glucagon sequence with a C18 fatty di-acid. Mazdutide is described as a modified oxyntomodulin analogue and is approved in China.
Survodutide has a multinational Phase 3 obesity trial and a strong liver-development programme. Mazdutide's pivotal published trials have mainly involved Chinese participants, and it has Chinese marketing authorisations. These differences affect what can be said about each evidence base.
Separate-trial weight percentages do not provide a fair direct comparison. The studies used different participants, placebo responses, target levels, durations, escalation schedules and estimands. Only a direct randomised trial within one protocol could answer a precise superiority question.
Survodutide should also not be called a stronger semaglutide. Semaglutide has a different receptor target, extensive approved-product experience and cardiovascular outcome evidence. A new compound may show larger changes in one study while having a different tolerability or evidence profile.
Does survodutide preserve muscle?
SYNCHRONIZE-1 imaging suggested that most body-composition change came from fat rather than lean volume. This is useful because large weight loss can include lean tissue. However, lean mass on a scan is not identical to skeletal muscle strength, physical function or muscle quality.
The imaging analysis involved a smaller subset than the main trial. Hydration and organ mass can affect lean-mass estimates. To prove clinically meaningful muscle preservation, researchers would ideally combine accurate body composition with strength, walking performance and other functional measurements.
The careful conclusion is that Phase 3 imaging produced an encouraging body-composition signal. It does not justify claiming that survodutide prevents muscle loss in every person.
What remains uncertain?
- Survodutide has not completed regulatory assessment for routine marketing.
- SYNCHRONIZE-CVOT provides Phase 3 cardiovascular safety evidence, but does not prove cardiovascular benefit or establish safety beyond the studied population and follow-up.
- The durability of weight and liver effects after treatment stops remains uncertain.
- The 19 per cent gastrointestinal withdrawal rate in SYNCHRONIZE-1 may affect real-world use.
- Liver-fat reduction does not yet prove prevention of cirrhosis, liver failure or death.
- The best balance between the 3.6 mg and 6.0 mg Phase 3 targets requires full benefit-risk assessment.
- Safety in pregnancy, breastfeeding, children and many people with severe organ disease is not established.
- Research products sold under the name have not been shown equivalent to the clinical material.
These limits do not make the trials uninformative. They show why a late-stage investigational medicine should be described differently from an approved treatment with years of post-marketing data.
Is survodutide approved or available?
As of 9 November 2026, survodutide remains investigational. Its developer has announced plans for global regulatory submissions. Positive Phase 3 results do not automatically create an approved medicine. A regulator must review manufacturing, clinical benefit, safety, proposed labelling and the company's evidence package.
FDA Breakthrough Therapy designation for MASH is not approval. Nor is participation in a clinical trial the same as routine availability. Trial sites supply a defined investigational product under a protocol, monitoring plan and ethics approval.
Online products labelled survodutide are not part of the Phase 3 programme unless supplied through an authorised study. The name alone does not establish sequence, fatty-side-chain placement, concentration, sterility or stability.
Frequently asked questions
Is survodutide a peptide?
Yes. It is an engineered glucagon-based peptide with a fatty-acid-related side chain that extends its time in the circulation.
Is survodutide approved?
No. It remains an investigational medicine as of 9 November 2026, despite positive Phase 3 results and new cardiovascular safety evidence.
Who is developing survodutide?
Boehringer Ingelheim leads development under a licence originating from Zealand Pharma, a Danish peptide-focused biotechnology company.
What was BI 456906?
BI 456906 was the development code used for the molecule now called survodutide.
Is survodutide the same as mazdutide?
No. Both activate GLP-1 and glucagon receptors, but they have different peptide structures, development programmes and regulatory status.
What does MASH mean?
MASH means metabolic dysfunction-associated steatohepatitis. It is fatty liver disease with inflammation and liver-cell injury, sometimes accompanied by fibrosis.
What is fibrosis?
Fibrosis is the build-up of scar tissue after repeated injury. In the liver it can progress through stages and may eventually lead to cirrhosis.
What was SYNCHRONIZE-1?
It was a 76-week, 725-participant global Phase 3 trial comparing two weekly survodutide targets with placebo in adults with obesity without type 2 diabetes.
Why are two weight-loss percentages reported for SYNCHRONIZE-1?
The treatment-regimen analysis included outcomes despite treatment discontinuation and found up to 13.0 per cent average loss. The efficacy analysis estimated continued-treatment effects and found up to 16.6 per cent. They answer different questions.
Does survodutide reverse fatty liver disease?
It substantially reduced measured liver fat in a Phase 3 trial. That does not yet prove prevention or reversal of cirrhosis, liver failure or other long-term clinical outcomes.
Does survodutide preserve muscle?
An imaging substudy suggested that a relatively small share of body-volume change came from lean tissue. This is encouraging but does not prove preservation of muscle strength or function in every person.
Are the administration levels in this guide dosage advice?
No. They describe clinical trials so readers can understand the evidence. Survodutide has no approved prescribing instructions.
Can a research product be assumed to match trial survodutide?
No. The same name does not prove the same structure, attachment chemistry, strength, purity, sterility or stability.
Bottom line
Survodutide is a late-stage investigational peptide with a serious human evidence base. Its modified glucagon-derived structure activates glucagon and GLP-1 receptors. Randomised studies have shown weight reduction, glucose lowering, MASH improvement and substantial liver-fat reduction in the populations tested.
The Phase 3 evidence also shows why benefit and tolerability must be discussed together. SYNCHRONIZE-1 reported meaningful weight loss, but gastrointestinal effects were common and 19 per cent of treated participants discontinued because of them. The liver-fat findings are important, yet longer studies must establish effects on fibrosis and clinical liver outcomes.
Survodutide is therefore best described as an investigational medicine with completed positive Phase 3 trials, not as an approved product or a proven answer for every person with obesity or liver disease.
Sources
Research reviewed through 9 November 2026.